The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort
NIL
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Inojosa H, Schriefer D, Atta Y, Dillenseger A, Proschmann U, Schleußner K, Woopen C, Ziemssen T, Akgün K.
Verlag
Publisher-Information
Vaccines. 2024; 12(3):265.
Link
Zur Publikation (externer Server)
https://doi.org/10.3390/vaccines12030265
Tags
Forschungsthemen
Multiple Sklerose
Neuroimmunologie
Andere
MSZ
Andere
NIL
2024
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis
Other
Jahr
2024
Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease
Multiple Sclerosis
Jahr
2024
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice
Multiple Sclerosis
Jahr
2024
MS brain health quality standards: a survey on the reality in clinical practice in Germany
Multiple Sclerosis
Jahr
2024
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study
MS Treatments
Jahr
2024
